MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Cytokinetics Inc

Închisă

SectorSănătate

40.38 0.22

Rezumat

Modificarea prețului

24h

Curent

Minim

39.4

Maxim

42

Indicatori cheie

By Trading Economics

Venit

11M

-150M

Vânzări

16M

17M

EPS

-1.26

Marjă de profit

-886.276

Angajați

498

EBITDA

13M

-125M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+102.24% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-723M

5.1B

Deschiderea anterioară

40.16

Închiderea anterioară

40.38

Sentimentul știrilor

By Acuity

20%

80%

41 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Cytokinetics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 iun. 2024, 15:26 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Comparație

Modificare preț

Cytokinetics Inc Așteptări

Obiectiv de preț

By TipRanks

102.24% sus

Prognoză pe 12 luni

Medie 81.4 USD  102.24%

Maxim 120 USD

Minim 62 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCytokinetics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

18 ratings

17

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

37.46 / 42.705Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

41 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.